AMO launches second phaco platform this year

November 13, 2015

The availability of a new cataract surgery platform from Abbott Medical Optics (AMO) marks the second phacoemulsification system launched by the company in the United States this year.

Las Vegas-The availability of a new cataract surgery platform from Abbott Medical Optics (AMO) marks the second phacoemulsification system launched by the company in the United States this year.

The Whitestar Signature Pro System provides a versatile solution designed to improve cataract surgeons’ efficiencies in the operating room, and to provide an excellent fit for their practice’s unique clinical demands and adaptability to meet their future needs, according to the company.

In addition to its on-demand fluidics and ultrasound efficiency, the system provides new analytics with the Cataract Analysis and Settings Application (CASA). The mobile analytics tool delivers performance metrics for the phacoemulsification procedure directly to an iPad device to aid the surgeon or administrator in managing the surgical suite.

 

The phacoemulsification platform “is designed for versatility and high-quality performance, allowing surgeons to easily optimize both their procedures and productivity, while simplifying their workflow in the operating room," said Leonard Borrmann, divisional vice president, research and development, Abbott.

Aside from this system, the company also launched its Compact Intuitiv System in April.